Boston Scientific Corporation (BSX)
Boston Scientific's 2026 Guidance Cut Puts Its Recovery to the Test
Boston Scientific's 2026 guidance cut tests its recovery as WATCHMAN weakness, EP share losses and delayed margin gains push a broader rebound toward 2028.
Should Investors Buy Boston Scientific Stock Despite Near-Term Risks?
Boston Scientific's cheaper valuation offers upside, but weaker guidance, share losses, higher debt and delayed catalysts favor patience.
Bear of the Day: Boston Scientific (BSX)
Boston Scientific ( BSX ) manufactures medical devices and products used in various interventional medical specialties worldwide, including cardiovascular and surgical categories. On July 29, BSX reported revenue of $5.44 billion for their June quarter, up 7.5% over the same period last year.
BSX Q2 Earnings Call Highlights WATCHMAN and EP Pressure
BSX faces WATCHMAN and EP pressures as management cuts outlook while highlighting cost savings and new product catalysts for future growth.
Boston Scientific Q2 Earnings Call Highlights
Boston Scientific NYSE: BSX reported second-quarter 2026 revenue growth at the high end of its guidance range and adjusted earnings per share above expectations, but lowered its full-year outlook as it faces slowing demand in its WATCHMAN left atrial appendage closure business and increased competitive pressure in U.S. electrophysiology.
Boston Scientific beats second quarter expectations, raises full-year outlook
Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst expectations for revenue and adjusted earnings, while raising its full-year sales outlook. The medical device company posted adjusted earnings per share of $0.86, ahead of the $0.83 consensus estimate, while revenue reached $5.442 billion, compared with analyst expectations of $5.37 billion.
Boston Scientific Corporation (BSX) Q2 2026 Earnings Call Transcript
Boston Scientific Corporation (BSX) Q2 2026 Earnings Call Transcript
Boston Scientific (BSX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Boston Scientific Q2 Earnings & Revenues Top Estimates, Stock Climbs
BSX beats Q2 earnings and revenue estimates as cardiovascular growth, strong APAC and LACA sales, and margin expansion lift shares in pre-market.
Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Estimates
Boston Scientific (BSX) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.75 per share a year ago.
Boston Scientific Cuts Outlook Ahead of Restructuring
Boston Scientific logged higher second-quarter results and cut its full-year outlook as it begins a new restructuring plan announced earlier this week.
Boston Scientific (BSX) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
